January 2025 Penny Stocks With Promising Potential

In This Article:

As global markets navigate a mixed economic landscape, with U.S. consumer confidence declining and major stock indices experiencing moderate gains, investors are keenly observing opportunities for growth. Penny stocks, often seen as smaller or newer companies with lower price points, continue to attract attention due to their potential for significant returns when backed by strong financials. This article highlights three promising penny stocks that combine solid balance sheets with the possibility of outsized gains, offering investors a chance to uncover hidden value in quality companies.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

DXN Holdings Bhd (KLSE:DXN)

MYR0.51

MYR2.54B

★★★★★★

Embark Early Education (ASX:EVO)

A$0.775

A$142.2M

★★★★☆☆

Hil Industries Berhad (KLSE:HIL)

MYR0.90

MYR298.75M

★★★★★★

MGB Berhad (KLSE:MGB)

MYR0.76

MYR449.66M

★★★★★★

Bosideng International Holdings (SEHK:3998)

HK$3.78

HK$41.63B

★★★★★★

Datasonic Group Berhad (KLSE:DSONIC)

MYR0.425

MYR1.18B

★★★★★★

Lever Style (SEHK:1346)

HK$0.86

HK$545.92M

★★★★★★

Begbies Traynor Group (AIM:BEG)

£0.964

£153.96M

★★★★★★

Stelrad Group (LSE:SRAD)

£1.42

£180.84M

★★★★★☆

Secure Trust Bank (LSE:STB)

£3.55

£67.7M

★★★★☆☆

Click here to see the full list of 5,824 stocks from our Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Antengene

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Antengene Corporation Limited is a biopharmaceutical company focused on developing novel oncology therapies in Greater China and internationally, with a market cap of HK$489.20 million.

Operations: The company generated CN¥56.07 million from its segment dedicated to the research, development, and commercialization of pharmaceutical products.

Market Cap: HK$489.2M

Antengene Corporation Limited, a biopharmaceutical company, has recently made strides with its drug XPOVIO®, achieving regulatory and reimbursement milestones in China and South Korea. Despite being unprofitable, Antengene has reduced losses by 23% annually over five years and maintains more cash than debt. The company's short-term assets significantly exceed both short- and long-term liabilities, providing a solid financial buffer. With sufficient cash runway for over a year even if free cash flow remains stable, Antengene's revenue is projected to grow substantially at 66.1% annually, driven by expanding indications for XPOVIO® across Asia-Pacific markets.